Synthesis and biological evaluation of α- and β-6-amido derivatives of 17-cyclopropylmethyl-3,14β-dihydroxy-4, 5α- epoxymorphinan: Potential alcohol-cessation agents

Journal of Medicinal Chemistry

Volumn 51, Issue 6, 2008, Pages 1913-1924

  Ghirmai, Senait ^a   Azar, Marc R ^b   Polgar, Wilma E ^c   Berzetei Gurske, Ilona ^c   Cashman, John R ^a  

^a HUMAN BIOMOLECULAR RESEARCH INSTITUTE   (United States)

^b Behavioral Pharma Inc   (United States)

^c SRI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6 [(3' DIMETHYLAMINO)BENZAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6ALPHA (BENZAMIDO)MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6ALPHA [(2',3',4',6' TETRA O BENZYL DEXTRO GLUCOPYRANOSYL)ACETAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6ALPHA [(3' METHOXY)BENZAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6ALPHA [(3',5' DIMETHOXY)BENZAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6ALPHA [(DEXTRO GLUCOPYRANOSYL)ACETAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA (BENZAMIDO)MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA (CINNAMOYLACETAMIDO)MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA (HYDROXYCINNAMOYLACETAMIDO)MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA [(2' PYRIDYL)ACETAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA [(3' HYDROXY)BENZAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA [(3' METHOXY)BENZAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA [(3' METHOXY)PHENYLACETAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA [(3' NITRO)BENZAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA [(3',4' DICHLORO)BENZAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA [(3',5' DIMETHOXY)BENZAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA [(4' AMINO)BENZAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA [(4' CARBOMETHOXY)BENZAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA [(4' CARBOXY)BENZAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA [(4' CHLORO)BENZAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA [(4' TERT BUTOXYCARBONYLAMINO)BENZAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXY 6BETA [(DEXTRO GLUCOPYRANOSYL)ACETAMIDO]MORPHINAN; 17 CYCLOPROPYLMETHYL 3,14BETA DIHYDROXY 4,5ALPHA EPOXYMORPHINAN; DELTA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR; MORPHINAN DERIVATIVE; MU OPIATE RECEPTOR; NALMEFENE; NALTREXONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALCOHOL CONSUMPTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CONTROLLED STUDY; DOSE RESPONSE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN TISSUE; HYDROGEN BOND; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RAT; STRUCTURE ACTIVITY RELATION;

ALCOHOL DRINKING; ALCOHOLISM; AMIDES; ANIMALS; BINDING, COMPETITIVE; DRUG EVALUATION, PRECLINICAL; ETHANOL; HUMANS; HYDROGEN BONDING; LIVER; MICE; MICROSOMES, LIVER; MOLECULAR STRUCTURE; MORPHINANS; NALTREXONE; RATS; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 41149158676     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701060e     Document Type: Article

References (40)

1. Grisel, J. E.; Grahame, N. J.; Mogil, J. S.; Belknap, J. K.; Low, M. J. Decreased voluntary ethanol consumption in transgenic mice lacking β-endorphin. Soc. Neurosci. Abstr. 1995, 21, 1699.
2. Gianoulakis, C.; Krishnan, B.; Thavundayil, J. Enhanced sensitivity of pituitary β-endophin to ethanol in subjects at high risk of alcoholism. Arch. Gen. Psychiatry 1996, 53, 250-257.
3. Roozen, H. G.; deWaele, R.; van der Windt, D. A.; van der Brink, W.; de Jong, C. A.; Kerkhof, A. J. A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence. Eur. Neuropsychopharmacol. 2006, 16, 311-323.
4. Pastor, R.; Aragon, C. M. The role of opioid receptor subtypes in the development of behavioral sensitization to ethanol. Neuropsychopharmacology 2006, 31, 1489-1499.
5. Bouza, C.; Angeles, M.; Munoz, A.; Amate, J. M. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review. Addiction 2004, 99, 811-828.
6. Croop, R. S.; Faulkner, E. B.; Labriola, D. F. The safety profile of naltrexone in the treatment of alcoholism. Result from a multicenter usage study. The naltrexone usage study group. Arch. Gen. Psychiatry 1997, 54, 1130-1135.
7. Mason, B. J.; Salvato, F. R.; Williams, L. D.; Ritvo, E. C.; Cutler, R. B. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch. Gen. Psychiatry 1999, 56, 719-724.
8. Anton, R. F.; Moak, D. H.; Waid, L. R.; Latham, P. K.; Malcolm, R. J.; Dias, J. K. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: Results of a placebo-controlled trial. Am. J. Psychiatry 1999, 156, 1758-1764.
9. Tabakoff, B.; Hoffman, P. L. Alcohol interactions with brain opiate receptors. Life Sci. 1983, 32, 197-204.
10. Garbutt, J. C.; Krantzler, H. R.; O'Malley, S. S.; Gastfriend, D. R.; Pettinati, H. M.; Silverman, B. L.; Loewy, J. W.; Ehrich, E. W. Vivitrex study group. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. J. Am. Med. Assoc. 2005, 293, 1617-1625.
11. Benjamin, D.; Grant, E. R.; Pohorecky, L. A. Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake freely moving rats. Brain Res. 1993, 621, 137-140.
12. Widdowson, P. S.; Holman, R. B. Ethanol-induced increase in endogenous dopamine release may involve endogenous opiates. J. Neurochem. 1992, 59, 157-163.
13. Herz, A. Endogenous opioid systems and alcohol addiction. Psychopharmacology 1997, 129, 99-111.
14. Ulm, R. R.; Volpicelli, J. R.; Volpicelli, L. A. Opiates and alcohol self-administration in animals. J. Clin. Psychiatry 1995, 56, 5-14.
15. Zhang, Y.; McCurdy, C. R.; Metzger, T. G.; Potoghese, P. S. Specific cross-linking of Lys233 and Cys235 in the μ opioid receptor by a reporter affinity label. Biochemistry 2005, 44, 2271-2275.
16. Hiroshi, N.; Kuniaki, K.; Takashi, E. Morphinan derivatives and its phramaceutical applications. U.S. Patent 20000541793.
17. Nagase, H.; Hayakawa, J.; Kawamura, K.; Kawal, K.; Takezawa, Y.; Matsuura, H.; Tajima, C.; Endo, T. Discovery of a structurally novel opioid κ-agonist derived from 4,5-epoxymorphinan. Chem. Pharm. Bull. 1998, 46, 366-369.
18. Mohamed, M. S.; Larson, D. L.; Takemori, A. E.; Portoghese, P. S. Activity of N-methyl-α- and β-funaltrexamine at opioid receptors. J. Med. Chem. 1986, 29, 1551-1553.
19. Ko, R. P.; Gupte, S. M.; Nelson, W. L. Opioid agonists and antagonists. 6,6-Hydrazi and 6-oximino derivatives of 14-hydroxydihydromorphinones. J. Med. Chem. 1984, 27, 1727-1729.
20. (b) Mohamed, M. S.; Portoghese, P. S. Stereoselectivity of the reduction of naltrexone oxime with borane. J. Org. Chem. 1986, 51, 105-106.
21. MacDougall, J. M.; Zhang, X. D.; Polgar, W. E.; Khroyan, T. V.; Toll, L.; Cashman, J. R. Synthesis and biological evaluation of some 6-arylamidomorphines as analogues of morphine-6-glucuronide. Bioorg. Med. Chem. 2004, 12, 5983-5990.
22. 35 S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 1995, 47, 848-854.
23. x and competitive drug antagonism. Br. J. Pharmacol. Chemother. 1949, 4, 277.
24. Tullman, R. H.; Hanzlik, R. P. Inactivation of cytochrome P-450 and monoamine oxidase by cyclopropylamines. Drug Metab. Rev. 1984, 15, 1163-1182.
25. Bondon, A.; Macdonald, T. L.; Harris, T. M.; Guengerich, F. P. Oxidation of cycloalkylamines by cytochrome P-450. J. Biol. Chem. 1989, 264, 1988-1997.
26. Denton, T. T.; Zhang, X. D.; Cashman, J. R. Nicotine-related alkaloids and metabolites as inhibitors of human cytochrome P-450 2A6. Biochem. Pharmacol. 2004, 67, 751-756.
27. Cashman, J. R.; MacDougall, J. M. Dynamic medicinal chemistry in the elaboration of morphine-6-glucuronide analogs. Curr. Top. Med. Chem. 2005, 5, 585-594.
28. Heyser, C. J.; Schulteis, G.; Koob, G. F. Increased ethanol self-administration after a period of imposed ethanol deprivation in rats trained in a limited access paradigm. Alcohol.: Clin. Exp. Res. 1997, 21, 784-791.
29. Heyser, C. J.; Roberts, A. J.; Shulteis, G.; Koob, G. F. Central administration of an opiate antagonist decreases oral ethanol self-administration in rats. Alcohol: Clin. Exp. Res. 1999, 23, 1468-1476.
30. Heyser, C. J.; Moc, K.; Koob, G. F. Effects of natrexone alone and in combination with acamprosate on the alcohol deprivation effect in rats. Neuropsychopharmacology 2003, 28, 1463-1473.
31. June, H. L.; Grey, C.; Warren-Reese, C.; Durr, L. F.; Ricks-cord, A.; Johnson, A.; McCane, S.; Williams, L. S.; Mason, D.; Cummings, R.; Lawrence, A. Alcohol.: Clin. Exp. Res. 1998, 22, 2174-2185.
32. Roberts, A. J.; Smith, A. D.; Weiss, F.; Rivier, C.; Koob, G. F. Estrous cycle effects on operant responding for ethanol in female rats. Alcohol.: Clin. Exp. Res. 1998, 22, 1564-1569.
33. Roberts, A. J.; McDonald, J. S.; Heyser, C. J.; Kieffer, B. L.; Matthes, H. W.; Koob, G. F.; Gold, L. H. μ-Opioid receptor knockout mice do not self-administer alcohol. J. Pharmacol. Exp. Ther. 2000, 293, 1002-1008.
34. Holter, S. M.; Spanagel, R. Effects of opiate antagonist treatment on the alcohol deprivation effect in long-term ethanol-experienced rats. Psychopharmacology 1999, 145, 360-369.
35. Spanagel, R.; Holter, S. M. Long-term alcohol self-administration with repeated alcohol deprivation phases: An animal model of alcoholism. Alcohol Alcohol. 1999, 34, 231-243.
36. MacDougall, J. M.; Zhang, X. D.; Polgar, W. E.; Khroyan, T. V.; Toll, L.; Cashman, J. R. Design, chemical synthesis, and biological evaluation of thiosaccharide analogues of morphine- and codeine-6-glucuronide. J. Med. Chem. 2004, 47, 5809-5815.
37. Stevens, W. C.; Jones, R. M.; Subramanian, G.; Metzger, T.; Ferguson, D. M.; Portoghese, P. S. Potent and selective indolomorphinan antagonists of the β-opioid receptor. J. Med. Chem. 2000, 43, 2759-2769.
38. Doss, G. A.; Baillie, T. A. Addressing metabolic activation as an integral component of drug design. Drug Metab. Rev. 2006, 38, 641-649.
39. Yano, J. K.; Denton, T. T.; Cerny, M. A.; Zhang, X.; Johnson, E. F.; Cashman, J. R. Synthetic inhibitors of cytochrome P-450 2A6: Inhibitory activity, difference spectra, mechanism of inhibition and protein cocrystalization. J. Med. Chem. 2006, 49, 6987-7001.
40. Rassnick, S.; Pulvirenti, L.; Koob, G. F. SDZ-205,152, a novel dopamine receptor agonist, reduces oral ethanol self-administration in rats. Alcohol 1993, 10, 127-132.